Get started
Work

A Phase 3 Randomized, Open-Label Study of Nivolumab (Anti-Pd-1; Bms-936558; Ono-4538) Versus Investigator'S Choice Chemotherapy (Icc) in Patients with Advanced Melanoma After Prior Anti-Ctla-4 Therapy

Year: 2014
Type: article
DOI: 10.1093/annonc/mdu438.34
Authors: J.S. Weber, D.R. Minor, S.P. D'Angelo, F.S. Hodi, R. Gutzmer, B. Neyns, C. Hoeller, N.I. Khushalani, W.H. Miller, J-J. Grob, C. Lao, G. Linette, K. Grossmann, J.C. Hassel, P. Lorigan, M. Maio, M. Sznol, A. Lambert, A. Yang, J. Larkin
Institutions: Moffitt Cancer Center, California Pacific Medical Center, Memorial Sloan Kettering Cancer Center, Dana-Farber Cancer Institute, Medizinische Hochschule Hannover, Vrije Universiteit Brussel, Medical University of Vienna, Roswell Park Comprehensive Cancer Center, Jewish General Hospital, Lady Davis Institute for Medical Research, McGill University, Aix-Marseille Université, Hôpital de la Timone, University of Michigan, Washington University in St. Louis, University of Utah, Huntsman Cancer Institute, University Hospital Heidelberg, National Center for Tumor Diseases, The Christie Hospital, The Christie NHS Foundation Trust, University of Siena, Yale Cancer Center, Yale University, Bristol-Myers Squibb (Belgium), Bristol-Myers Squibb (United States), Royal Marsden Hospital
Language: English
Subfield: Oncology
Field: Medicine
Open Access status: bronze
OpenAlex ID: W2404196663
FWCI: 8.65
Cites:
Cited by: 73
Related to: 10